India Pharma Outlook Team | Thursday, 15 October 2026
Finding new drug targets for serious liver and heart diseases has been frustratingly slow.
Patients with metabolic dysfunction-associated steatohepatitis and certain heart-muscle conditions still lack strong treatment options because scientists struggle to identify the true biological drivers.
AstraZeneca is now betting USD 40 million that artificial intelligence can change that pace.
The British drugmaker has teamed up with AI specialist insitro to hunt for novel drug targets in these hard-to-treat areas. The deal puts real money behind the claim that machine learning can reveal causal disease biology faster than traditional methods and open paths to better medicines.
AstraZeneca will pay insitro USD 40 million upfront. The California biotech stands eligible for up to about USD 1.46 billion in development and commercial milestones plus single-digit royalties on future sales.
The multi-year collaboration focuses on metabolic dysfunction-associated steatohepatitis, or MASH, a severe form of fatty liver disease, and cardiomyopathies, a group of conditions that damage the heart muscle.
Insitro will apply its AI platform, which combines lab-grown cell models with machine learning, to identify causal disease biology. The company will advance AstraZeneca-nominated targets from discovery through to development-candidate stage. AstraZeneca will then run and fund the clinical trials and hold exclusive worldwide rights to the selected programs.
Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market
MASH and cardiomyopathies remain prevalent and underdiagnosed. Researchers have long found it difficult to pinpoint their root biological drivers, which has limited the arrival of effective therapies.
High-content data from human and cellular sources holds valuable signals, yet traditional methods often miss the critical connections. Insitro CEO Daphne Koller notes that applying AI to these complex datasets can unlock greater discovery power and reveal novel genetic insights.
AstraZeneca Executive Sharon Barr adds that selecting new targets ranks among the hardest tasks in research and development. By the time a pathway appears in major journals, it is no longer novel. Identifying unique connections early and testing them in cellular systems keeps the company ahead.
Large pharmaceutical companies increasingly partner with AI specialists to improve target discovery. insitro has already worked with other major firms, including expanded collaborations that have advanced portfolios in areas such as ALS and predictive models for small molecules.
The new AstraZeneca agreement continues that pattern while giving the biotech additional resources as it develops its own early-stage programs, which include work on liver fat and fibrosis.
This collaboration offers a practical test of whether “causal AI” can deliver better drug targets. Insitro’s platform aims to move beyond correlation and identify the actual biological mechanisms driving disease.
Cardiomyopathies represent a quieter but potentially significant opportunity alongside the more widely discussed MASH indication. Success would mean AstraZeneca gains proprietary targets that traditional discovery routes have overlooked.
If the AI performs as hoped, the real payoff will not be the USD 40 million upfront payments. It will be new medicines for diseases that have long resisted conventional research approaches.
.jpg)
